news
FDA approves at-home Leqembi shots for Alzheimer's
The FDA just approved a subcutaneous dose of lecanemab (Leqembi), meaning some adults with early Alzheimer's can now inject the drug at home. Previously, patients had to start treatment with an intravenous infusion. Research presented at the Alzheimer’s Association International Conference showed stable outcomes over 17 months for patients on both IV and subcutaneous doses.
The FDA just approved a subcutaneous dose of lecanemab (Leqembi), meaning some adults with early Alzheimer's can now inject the drug at home. Previously, patients had to start treatment with an intravenous infusion. Research presented at the Alzheimer’s Association International Conference showed stable outcomes over 17 months for patients on both IV and subcutaneous doses.
The architecture take
The ability to self-administer Leqembi at home via injection changes everything for people living with Alzheimer's and their caregivers. This isn't just a matter of convenience; it’s about control and reducing the massive logistical and emotional burden of regular clinic visits for infusions. When therapy for cognitive decline becomes less invasive and more integrated into daily life, adherence goes up, and the mental load on families drops. This move by the FDA acknowledges that the 'how' of treatment delivery is just as critical as the 'what' for long-term conditions. Look for other complex, chronic care protocols to follow suit, pushing more treatments out of the clinic and into patients' hands. It's DIY medicine where it makes sense, and for neurological conditions where every moment counts, it's a huge win.